SLDB · Insider Trading
Solid Biosciences Inc. Common Stock
Every open-market purchase and sale reported by SLDB officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-26 | Ilan Ganot | Director | A | +150,000 deriv. | — |
| 2026-10-20 | Gabriel Brooks | Chief Medical Officer | MIXED | +5,376 | −$24.58K |
| 2026-10-06 | Ian F Smith | Director | M | +3,440 | — |
| 2026-07-07 | Ian F Smith | Director | M | +3,440 | — |
| 2026-06-11 | Martin I Freed | Director | A | +77,500 deriv. | — |
| 2026-06-11 | Adam Leo Stone | Director | A | +77,500 deriv. | — |
| 2026-06-11 | Ian F Smith | Director | A | +77,500 deriv. | — |
| 2026-06-11 | Clare Kahn | Director | A | +77,500 deriv. | — |
| 2026-06-11 | Sukumar Nagendran | Director | A | +77,500 deriv. | — |
| 2026-06-11 | Georgia Keresty | Director | A | +77,500 deriv. | — |
| 2026-06-11 | Lynne Marie Sullivan | Director | A | +77,500 deriv. | — |
| 2026-06-11 | PERCEPTIVE ADVISORS LLC | Director | A | +77,500 deriv. | — |
| 2026-06-11 | Ilan Ganot | Director | A | +77,500 deriv. | — |
| 2026-04-21 | Gabriel Brooks | Chief Medical Officer | A | +58,847 deriv. | — |
| 2026-04-21 | Paul Herzich | Chief Technology Officer | A | +54,925 deriv. | — |
| 2026-04-21 | David T Howton | Chief Operating Officer | A | +79,341 deriv. | — |
| 2026-04-21 | Alexander Cumbo | President and CEO | A | +169,401 deriv. | — |
| 2026-04-21 | Jessie Hanrahan | Chief Regulatory Officer | A | +54,925 deriv. | — |
| 2026-04-21 | Kevin Tan | CFO & Treasurer | A | +56,647 deriv. | — |
| 2026-04-02 | Ian F Smith | Director | M | +3,441 | — |
| 2026-03-11 | Joseph Edelman | Director | A | +8,912,655 deriv. | — |
| 2026-02-18 | Gabriel Brooks | Chief Medical Officer | MIXED | +10,937 | — |
| 2026-02-18 | Alexander Cumbo | President and CEO | MIXED | +13,387 | −$96.92K |
| 2026-02-18 | Jessie Hanrahan | Chief Regulatory Officer | MIXED | +3,991 | −$24.07K |
| 2026-02-18 | Kevin Tan | CFO & Treasurer | MIXED | +5,221 | −$31.47K |
| 2026-02-18 | Paul Herzich | Chief Technology Officer | MIXED | +3,571 | −$21.06K |
| 2026-02-18 | David T Howton | Chief Operating Officer | MIXED | +7,218 | −$43.49K |
| 2026-02-18 | Ilan Ganot | Director | MIXED | +2,203 | −$15.48K |
| 2026-02-06 | Gabriel Brooks | Chief Medical Officer | Sell | −12,616 | −$81.27K |
| 2026-02-06 | David T Howton | Chief Operating Officer | Sell | −18,894 | −$121.71K |
| 2026-02-06 | Ilan Ganot | Director | Sell | −7,205 | −$46.41K |
| 2026-02-06 | Paul Herzich | Chief Technology Officer | Sell | −10,905 | −$70.25K |
| 2026-02-06 | Kevin Tan | CFO & Treasurer | Sell | −14,783 | −$95.23K |
| 2026-02-06 | Alexander Cumbo | President and CEO | Sell | −48,913 | −$315.09K |
| 2026-02-06 | Jessie Hanrahan | Chief Regulatory Officer | Sell | −12,348 | −$79.54K |
| 2026-02-02 | Jessie Hanrahan | Chief Regulatory Officer | MIXED | +56,015 | −$170.80K |
| 2026-02-02 | Ilan Ganot | Director | M | +15,000 | — |
| 2026-02-02 | Alexander Cumbo | President and CEO | MIXED | +189,543 | −$516.61K |
| 2026-02-02 | Kevin Tan | CFO & Treasurer | MIXED | +62,884 | −$172.75K |
| 2026-02-02 | Paul Herzich | Chief Technology Officer | MIXED | +53,350 | −$168.97K |
| 2026-02-02 | Gabriel Brooks | Chief Medical Officer | MIXED | +58,737 | −$182.39K |
| 2026-02-02 | David T Howton | Chief Operating Officer | MIXED | +83,845 | −$243.13K |
| 2026-01-30 | Ilan Ganot | Director | MIXED | +4,082 | −$1.26K |
| 2026-01-13 | Kevin Tan | CFO & Treasurer | MIXED | +5,546 | −$30.06K |
| 2026-01-07 | Ian F Smith | Director | M | +4,573 | — |
| 2026-01-06 | Ilan Ganot | Director | MIXED | +1,941 | −$5.72K |
| 2025-12-04 | David T Howton | Chief Operating Officer | MIXED | +8,119 | −$25.20K |
| 2025-12-04 | Jessie Hanrahan | Chief Regulatory Officer | MIXED | +7,379 | −$22.91K |
| 2025-12-04 | Alexander Cumbo | President and CEO | MIXED | +17,804 | −$55.23K |
| 2025-12-04 | Paul Herzich | Chief Technology Officer | MIXED | +4,538 | −$13.80K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Bain Capital Life Sciences Fund II, L.P. | 10%+ Owner | 5,034,582 | $35.90M |
| Adage Capital Management, L.P. | 10%+ Owner | 4,248,084 | $30.29M |
| PERCEPTIVE LIFE SCIENCES MASTER FUND LTD | Director | 449,987 | $3.21M |
| Alexander Cumbo | President and CEO | 235,405 | $1.68M |
| Ian F Smith | Director | 141,585 | $1.01M |
| Ilan Ganot | Director | 129,429 | $922.83K |
| RA CAPITAL MANAGEMENT, L.P. | Director | 109,661 | $781.88K |
| David T Howton | Chief Operating Officer | 105,077 | $749.20K |
| Kevin Tan | CFO & Treasurer | 104,826 | $747.41K |
| Gabriel Brooks | Chief Medical Officer | 97,241 | $693.33K |
| Jessie Hanrahan | Chief Regulatory Officer | 78,452 | $559.36K |
| Paul Herzich | Chief Technology Officer | 76,254 | $543.69K |
| PERCEPTIVE ADVISORS LLC | Director | 73,107 | $521.25K |
| Joseph Edelman | Director | 73,107 | $521.25K |
| Martin I Freed | Director | 3,584 | $25.55K |
| Clare Kahn | Director | 2,960 | $21.10K |
| Sukumar Nagendran | Director | 2,284 | $16.28K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the SLDB quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.